A human erythropoietin-albumin fusion protein tailored for enhanced plasma half-life and delivery across mucosal surfaces
This study presents a tailored erythropoietin fused to engineered albumin for extended plasma half-life after intravenous and subcutaneous delivery in mice. Following invasive or intranasal delivery, it promotes sustained erythrocyte proliferation.